Castellana, MarcoGrani, GiorgioRadzina, MaijaGuerra, VitoGiovanella, LucaDeandrea, MaurilioNgu, RoseDurante, CosimoTrimboli, Pierpaolo2022-08-162022-08-162020-09Castellana, M, Grani, G, Radzina, M, Guerra, V, Giovanella, L, Deandrea, M, Ngu, R, Durante, C & Trimboli, P 2020, 'Performance of EU-TIRADS in malignancy risk stratification of thyroid nodules : A meta-analysis', European Journal of Endocrinology, vol. 183, no. 3, pp. 255-264. https://doi.org/10.1530/EJE-20-02040804-4643https://dspace.rsu.lv/jspui/handle/123456789/9359Publisher Copyright: © 2020 European Society of Endocrinology. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.Objective: Several thyroid imaging reporting and data systems (TIRADS) ha ve been proposed to stratify the malignancy risk of thyroid nodule by ultrasound. The TIRADS by the Europea n Thyroid Association, namely EU-TIRADS, was the last one to be published. Design: We conducted a meta-analysis to assess the prevalence of malig nancy in each EU-TIRADS class and the performance of EU-TIRADS class 5 vs 2, 3 and 4 in detecting mal ignant lesions. Methods: Four databases were searched until December 2019. Original art icles reporting the performance of EU-TIRADS and adopting histology as reference standard were inc luded. The number of malignant nodules in each class and the number of nodules classified as true/false positiv e/negative were extracted. A random-effects model was used for pooling data. Results: Seven studies were included, evaluating 5672 thyroid nodules. The prevalence of malignancy in each EU-TIRADS class was 0.5% (95% CI: 0.0-1.3), 5.9% (95% CI: 2.6-9 .2), 21.4% (95% CI: 11.1-31.7), and 76.1% (95% CI: 63.7-88.5). Sensitivity, specificity, PPV, NPV, LR+, LR- A nd DOR of EU-TIRADS class 5 were 83.5% (95% CI: 74.5-89.8), 84.3% (95% CI: 66.2-93.7), 76.1% (95% CI: 63.7-88.5), 85.4% (95 % CI: 79.1-91.8), 4.9 (95% CI: 2.9-8.2), 0.2 (95% CI: 0.1-0.3), and 24.5 (95% CI: 11.7-51.0), respectively. A further improved performance was found after excluding two studies because of limited sample size and low prevalence of ma lignancy in class 5. Conclusions: A limited number of studies generally conducted using a retros pective design was found. Acknowledging this limitation, the performance of EU-TIRADS in stratifying th e risk of thyroid nodules was high. Also, EU-TIRADS class 5 showed moderate evidence of detecting malignant lesions.101058206enginfo:eu-repo/semantics/openAccess3.2 Clinical medicine1.1. Scientific article indexed in Web of Science and/or Scopus databaseEndocrinology, Diabetes and MetabolismEndocrinologySDG 3 - Good Health and Well-being/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article10.1530/EJE-20-0204http://www.scopus.com/inward/record.url?scp=85088846666&partnerID=8YFLogxK